Nature Communications (Aug 2024)

RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening

  • Shrestha Ghosh,
  • Mileena T. Nguyen,
  • Ha Eun Choi,
  • Maximilian Stahl,
  • Annemarie Luise Kühn,
  • Sandra Van der Auwera,
  • Hans J. Grabe,
  • Henry Völzke,
  • Georg Homuth,
  • Samuel A. Myers,
  • Cory M. Hogaboam,
  • Imre Noth,
  • Fernando J. Martinez,
  • Gregory A. Petsko,
  • Laurie H. Glimcher

DOI
https://doi.org/10.1038/s41467-024-51336-3
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Telomere shortening is a prominent hallmark of aging and is emerging as a characteristic feature of Myelodysplastic Syndromes (MDS) and Idiopathic Pulmonary Fibrosis (IPF). Optimal telomerase activity prevents progressive shortening of telomeres that triggers DNA damage responses. However, the upstream regulation of telomerase holoenzyme components remains poorly defined. Here, we identify RIOK2, a master regulator of human blood cell development, as a critical transcription factor for telomere maintenance. Mechanistically, loss of RIOK2 or its DNA-binding/transactivation properties downregulates mRNA expression of both TRiC and dyskerin complex subunits that impairs telomerase activity, thereby causing telomere shortening. We further show that RIOK2 expression is diminished in aged individuals and IPF patients, and it strongly correlates with shortened telomeres in MDS patient-derived bone marrow cells. Importantly, ectopic expression of RIOK2 alleviates telomere shortening in IPF patient-derived primary lung fibroblasts. Hence, increasing RIOK2 levels prevents telomere shortening, thus offering therapeutic strategies for telomere biology disorders.